Is xenotransplantation of embryonic stem cells a realistic option?

Transplantation. 2007 Feb 15;83(3):333-5. doi: 10.1097/01.tp.0000247798.68218.29.

Abstract

To test the purported immune privilege of embryonic stem cells (ESC) in the challenging setting of xenotransplantation, 14 immunocompetent baboons were subjected to a coronary artery occlusion-reperfusion sequence and, two weeks later, randomized to receive in-scar injections of culture medium or cardiac-committed mouse ESC engineered to express fluorescent reporter genes driven by cardiac-specific promoters. Two months after transplantation, left ventricular function, as assessed by echocardiography, deteriorated to a similar extent in control and treated baboons. This correlated with failure to identify the grafted cells by X-gal histology and immunofluorescence. Rejection did not seem to be mediated by xenoantibodies, but rather by T lymphocytes and natural killer cells as suggested by positive immunostaining for CD3 and CD56 early after transplantation. There was no increase in circulating levels of regulatory T cells. These data raise a cautionary note about the immune privilege of ESC and suggest that from a mere immunologic standpoint, ESC xenotransplantation is likely to be an unrealistic challenge.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD56 Antigen / analysis
  • Electrocardiography
  • Embryonic Stem Cells / immunology*
  • Embryonic Stem Cells / transplantation*
  • Graft Rejection / immunology*
  • Killer Cells, Natural / immunology
  • Mice
  • Myocardial Infarction / surgery*
  • Papio
  • T-Lymphocytes, Regulatory / immunology
  • Transplantation, Heterologous / immunology*
  • Ventricular Dysfunction, Left / diagnosis

Substances

  • CD56 Antigen